课题基金 / 基金详情

项目摘要

项目成果

Yingfei Wang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project summary Poly(ADP-ribose) (PAR) polymerase-1 (PARP-1) plays a pivotal role in DNA damage response. It can be activated either by the DNA alkylating agents abundant in our environment, or the byproducts of the cellular oxidative stress or toxicity. In response to mild DNA damage, PARP-1 facilitates DNA repair process. Blockage of PARP-1 activity sensitizes cancer cells to death. This concept is well supported by PARP inhibitor olaparib used in clinic for cancer therapy. In contrast, in response to severe DNA damage, excessive activation of PARP-1 causes the large DNA fragments and caspase-independent cell death designated parthanatos, which occurs in many organ systems and is widely involved in different neurologic and non-neurologic diseases, including ischemia-reperfusion injury after stroke and myocardial infarction, glutamate excitotoxicity, neurodegenerative diseases, inflammatory injury, reactive oxygen species–induced injury. This type of cell death is profoundly prevented by pharmacological inhibition or genetic deletion of PARP-1. The importance of PARP-1 in cell death has also been appreciated in the cancer field as alkylating agents have been used in chemotherapy to kill cancer cells. Therefore, these PARP-1 studies raise a huge knowledge gap how PARP-1 signaling is regulated in DNA damage or oxidative stress, leading to either DNA repair/cell survival or DNA damage/cell death. Previous works from the PI have revealed the molecular mechanisms by which PAR triggers apoptosis inducing factor (AIF) release from the mitochondria and translocation to the nucleus, leading to PARP-1 dependent cell death (parthanatos). Recently PI further made an important discovery by identifying macrophage migration inhibitory factor (MIF) as a novel nuclease and an executioner in parthanatos, which cleaves genomic DNA into large fragments and causes neuron and cancer cell death. However, many fundamental questions, including 1) how MIF nuclease activity is regulated in response to DNA damage and oxidative stress in neurons and cancer cells; 2) how PARP-1 signaling in DNA damage is regulated and switched between cell death and cell survival in neurons and cancer cells; 3) how to effectively interfere PARP- 1 signaling in DNA damage to prevent excess neuron loss but enhance cancer cell death, have not yet been answered. The goals of this MIRA project are to obtain a comprehensive molecular understanding of PARP-1 signaling in DNA damage and to discover how PARP-1 signaling can be manipulated in response to mild or severe DNA damage thereby preventing neuronal cell death but enhancing tumor cell death. If successful, the knowledge achieved from these studies will directly impact the clinical application of PARP inhibitors for treatment of cancer or stroke. Moreover, the comprehensive understanding of the regulatory networks of PARP-1 signaling may also lead to the development of novel therapeutic strategies for the treatment of human diseases caused by PARP-1 activation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of KDM6B in Alzheimer’s disease related dementia
  • 批准号:
    10739281
  • 项目类别:
  • 资助金额:
    $74.95万
  • 财政年份:
    2023
  • 负责人:
    Yingfei Wang
  • 依托单位:
The role of AIF3 in neurodegeneration of Alzheimer's disease
  • 批准号:
    10190767
  • 项目类别:
  • 资助金额:
    $56.9万
  • 财政年份:
    2019
  • 负责人:
    Yingfei Wang
  • 依托单位:
The role of AIF3 in neurodegeneration of Alzheimer's disease
  • 批准号:
    10626004
  • 项目类别:
  • 资助金额:
    $56.94万
  • 财政年份:
    2019
  • 负责人:
    Yingfei Wang
  • 依托单位:
The role of AIF3 in neurodegeneration of Alzheimer's disease
  • 批准号:
    10434704
  • 项目类别:
  • 资助金额:
    $56.94万
  • 财政年份:
    2019
  • 负责人:
    Yingfei Wang
  • 依托单位:
国内基金
海外基金
中药活性成分土木香内酯靶向 TXNL2 通过caspase-3/GSDME 介导的细胞焦亡抗未分化甲状腺癌的机制研究
  • 批准号:
    ZCLQN26H2801
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    温庆良
  • 依托单位:
壮骨止痛胶囊通过NLRP3/Caspase-1/GSDMD信号通路调控神经肽介导PMOP大鼠脑-肠-骨轴的机制研究
  • 批准号:
    2026JJ81070
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    陈沙
  • 依托单位:
骨痹汤调控NLRP3/ASC/Caspase-1介导的细胞焦亡治疗膝骨关节炎的作用及机制研究
  • 批准号:
    2026JJ80380
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    郑艳艳
  • 依托单位:
TIRAP调控NLRP3/Caspase-1/GSDMD通路诱导KOA软骨细胞焦亡机制的研究